Invasive Candidiasis – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Invasive candidiasis is an infection caused by a type of fungus called Candida is a serious infection that can affect the blood, heart, brain, eyes, bones, and other parts of the body. Candida species are frequent colonizers of the human alimentary tract and skin that have emerged as important nosocomial pathogens, in tandem with advances in modern medical therapeutics. Risk factors for invasive candidiasis include exposure to broad-spectrum antibiotics and cancer chemotherapy, advanced care of premature neonates, major abdominal surgery, organ transplantation, prolonged stay in an intensive care setting, implanted medical devices such as vascular catheters and prosthetic heart valves, and parenteral feeding. Recent treatment directives have been shaped by the widespread introduction of echinocandins, highly potent and safe antifungals, into clinical use, as well as important changes in drug susceptibility patterns and the emergence of known and novel drug-resistant Candida species. Advances in molecular diagnostics have the potential to guide the early targeted treatment of high-risk patients.
The global
incidence of cases of Invasive candidiasis has been estimated between 550,000
to 825,00 cases annually, with an associated crude mortality rate varies
between 22% to 43%.
The competitive
landscape of Invasive Candidiasis includes country-specific approved and
pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of Invasive
Candidiasis across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Invasive
Candidiasis Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 caspofungin acetate Merck
Sharp & Dohme Corp. Phase 3
2 Anidulafungin Pfizer Phase 3
3 FK463 Astellas Pharma
Inc Phase 2
4 APX001 Amplyx
Pharmaceuticals Phase 2
5 Rezafungin Cidara
Therapeutics Inc. Phase 3
6 Ibrexafungerp Scynexis,
Inc. Phase 3
Comments
Post a Comment